Jörn C. Albring

3.6k total citations · 1 hit paper
26 papers, 2.4k citations indexed

About

Jörn C. Albring is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Jörn C. Albring has authored 26 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 12 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Jörn C. Albring's work include T-cell and B-cell Immunology (12 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Immune Cell Function and Interaction (10 papers). Jörn C. Albring is often cited by papers focused on T-cell and B-cell Immunology (12 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Immune Cell Function and Interaction (10 papers). Jörn C. Albring collaborates with scholars based in Germany, United States and Switzerland. Jörn C. Albring's co-authors include Kenneth M. Murphy, Ansuman T. Satpathy, Xiaodi Wu, Wumesh KC, Brian T. Edelson, Deepta Bhattacharya, Theresa L. Murphy, Nicole M. Kretzer, Masako Kohyama and Theresa L. Murphy and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Blood.

In The Last Decade

Jörn C. Albring

25 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

2010 586 citations Brian T. Edelson, Wumesh KC et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jörn C. Albring Germany	14	1.9k	478	372	157	156	26	2.4k
Isharat Yusuf United States	13	2.3k 1.2×	493 1.0×	454 1.2×	165 1.1×	122 0.8×	13	2.8k
Irene Gramaglia United States	18	1.7k 0.9×	378 0.8×	445 1.2×	137 0.9×	111 0.7×	26	2.5k
Pierre Vantourout United Kingdom	19	2.0k 1.1×	391 0.8×	676 1.8×	193 1.2×	88 0.6×	25	2.5k
Noriko Arase Japan	20	1.9k 1.0×	402 0.8×	395 1.1×	318 2.0×	164 1.1×	53	2.5k
Carlos G. Briseño United States	23	2.2k 1.1×	665 1.4×	676 1.8×	131 0.8×	99 0.6×	28	2.7k
Megan Barnden Australia	14	1.9k 1.0×	467 1.0×	376 1.0×	239 1.5×	83 0.5×	15	2.4k
Naoshi Sugimoto Japan	19	1.2k 0.6×	633 1.3×	300 0.8×	109 0.7×	223 1.4×	48	2.0k
Guillaume Darrasse-Jèze France	15	2.2k 1.1×	326 0.7×	404 1.1×	130 0.8×	80 0.5×	24	2.5k
Janet E. Buhlmann United States	13	1.4k 0.7×	342 0.7×	473 1.3×	126 0.8×	83 0.5×	21	2.0k
Ninghai Wang United States	27	1.7k 0.9×	257 0.5×	404 1.1×	241 1.5×	228 1.5×	39	2.1k

Countries citing papers authored by Jörn C. Albring

Since Specialization

Citations

This map shows the geographic impact of Jörn C. Albring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörn C. Albring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörn C. Albring more than expected).

Fields of papers citing papers by Jörn C. Albring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörn C. Albring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörn C. Albring. The network helps show where Jörn C. Albring may publish in the future.

Co-authorship network of co-authors of Jörn C. Albring

This figure shows the co-authorship network connecting the top 25 collaborators of Jörn C. Albring. A scholar is included among the top collaborators of Jörn C. Albring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörn C. Albring. Jörn C. Albring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reicherts, Christian, Eva Eßeling, Julia Marx, et al.. (2025). High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia—A Retrospective Single-Center Study. Transplantation and Cellular Therapy. 31(10). 820.e1–820.e11.

Berning, Philipp, Christian Reicherts, Julia Marx, et al.. (2024). Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone Marrow Transplantation. 59(8). 1097–1106. 1 indexed citations

Albring, Jörn C., et al.. (2024). Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood Advances. 8(8). 1934–1945. 1 indexed citations

Roll, Wolfgang, Georg Evers, Jörn C. Albring, et al.. (2021). Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive Therapy. Transplantation and Cellular Therapy. 27(7). 603–610. 8 indexed citations

Roll, Wolfgang, Philipp Schindler, Max Masthoff, et al.. (2021). 18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD). BMC Cancer. 21(1). 1015–1015. 7 indexed citations

Stelmach, Patrick, Klaus Wethmar, Christoph Groth, et al.. (2020). Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Clinical Lymphoma Myeloma & Leukemia. 20(10). e724–e733. 10 indexed citations

Wethmar, Klaus, Eva Eßeling, Linus Angenendt, et al.. (2020). Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. Bone Marrow Transplantation. 55(7). 1410–1420. 7 indexed citations

Albring, Jörn C., et al.. (2018). Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 53(7). 807–819. 2 indexed citations

Kretzer, Nicole M., Derek J. Theisen, Roxane Tussiwand, et al.. (2016). RAB43 facilitates cross-presentation of cell-associated antigens by CD8α+ dendritic cells. The Journal of Experimental Medicine. 213(13). 2871–2883. 63 indexed citations

10.

Grajales‐Reyes, Gary E., Arifumi Iwata, Jörn C. Albring, et al.. (2015). Batf3 maintains autoactivation of Irf8 for commitment of a CD8α+ conventional DC clonogenic progenitor. Nature Immunology. 16(7). 708–717. 269 indexed citations

11.

Sauer, Tim, Gerda Silling, Christoph Groth, et al.. (2015). Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. Bone Marrow Transplantation. 50(4). 485–492. 21 indexed citations

12.

KC, Wumesh, Ansuman T. Satpathy, Aaron S. Rapaport, et al.. (2014). L-Myc expression by dendritic cells is required for optimal T-cell priming. Nature. 507(7491). 243–247. 62 indexed citations

13.

Langer, Ellen M., Jennifer G. Gill, Ansuman T. Satpathy, et al.. (2012). Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation. Blood. 120(2). 335–346. 39 indexed citations

14.

Satpathy, Ansuman T., Wumesh KC, Jörn C. Albring, et al.. (2012). Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. The Journal of Experimental Medicine. 209(6). 1135–1152. 458 indexed citations

15.

Satpathy, Ansuman T., Xiaodi Wu, Jörn C. Albring, & Kenneth M. Murphy. (2012). Re(de)fining the dendritic cell lineage. Nature Immunology. 13(12). 1145–1154. 327 indexed citations

16.

Albring, Jörn C., Michelle M. Sandau, Aaron S. Rapaport, et al.. (2010). Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. The Journal of Experimental Medicine. 207(12). 2551–2559. 55 indexed citations

17.

Edelson, Brian T., Wumesh KC, Masako Kohyama, et al.. (2010). Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells. The Journal of Experimental Medicine. 207(4). 823–836. 586 indexed citations breakdown →

18.

Stelljes, Matthias, Jörn C. Albring, Hans‐Gerd Pauels, et al.. (2007). Differential Requirement for a Cellular Type-1 Immune Response in Tumor-Associated Versus Alloantigen-Targeted GvT Effects. Transplantation. 83(3). 314–322. 2 indexed citations

19.

Albring, Jörn C., Jens‐Oliver Koopmann, Günter J. Hämmerling, & Frank Momburg. (2003). Retrotranslocation of MHC class I heavy chain from the endoplasmic reticulum to the cytosol is dependent on ATP supply to the ER lumen. Molecular Immunology. 40(10). 733–741. 10 indexed citations

20.

Koopmann, Jens‐Oliver, Jörn C. Albring, Eva N. Huter, et al.. (2000). Export of Antigenic Peptides from the Endoplasmic Reticulum Intersects with Retrograde Protein Translocation through the Sec61p Channel. Immunity. 13(1). 117–127. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact